COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Boden WE et al. ACC 2007.

unstable angina undergoing PCI.
PLATO Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. Held C et al. ACC 2010.
JPAD The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial. Efficacy of Low-Dose Aspirin Therapy for the Primary Prevention.
EXCELLENT The randomized comparison of 6-month vs 12-month duration of dual antiplatelet therapy after the implantation of drug eluting stent. Gwon H-C,
FUTURA/OASIS-8 Low versus standard dose unfractionned heparin for percutaneous coronary intervention in acute coronary syndrome patients treated with fondaparinux.
CLEAR PLATELETS Variabilité génétiquement déterminée de l’effet du clopidogrel Influence du polymorphism du CYP2C19 sur les effets antiplaquettaires du.
GRACE The Global Registry of Acute Coronary Events Montalescot G et al.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.
Apixaban versus warfarin in patients with atrial fibrillation
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
RE-LY Randomization Evaluation of Long-Term Anticoagulation Therapy Connolly S.J et al. N Engl J Med 2009 ; 361.
Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ISAR-REACT Anti-GPIIbIIIa (abciximab) en complément d’une dose de charge en clopidogrel avant angioplastie avec mise en place d’une endoprothèse coronaire.
EXPLORE-Xa Betrixaban Compared With Open‑Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation. Ezekowitz MD et al. ACC 2010.
Actualités sur les antiagrégants plaquettaires
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
Platelet inhibition with cangrelor in patients undergoing PCI.
PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
PRAGUE 7 Primary angioplasty in patients from general hospital transported to cathlab units with/without emergency thrombolysis Widimski P et al.
Intravenous platelet blockade with cangrelor during PCI.
NORDISTEMI Norwegian study on district treatment of ST-elevation myocardial infarction Halvorsen S. et al.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
AVERROES Apixaban versus acetylsalicylic acid (ASA) to reduce the risk of stroke Connolly S et al. ESC 2010.
Revascularisation coronaire : ATL-endoprothèses ou chirurgie ?
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
ISAR-REACT 4 The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Kastrati A et al. AHA.
Stents et anti-agrégants plaquettaires.
OASIS-5 Comparaison du fondaparinux à l’énoxaparine dans le syndrome coronarien aigu Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Prasugrel vs Clopidogrel for Patients managed with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography : a secondary,
ETUDE ASPIRE: LOW-DOSE ASPIRIN FOR PREVENTING RECURRENT VENOUS THROMBOEMBOLISM Timothy A. Brighton, M.B., B.S., John W. Eikelboom, M.B., B.S., Kristy Mann,
ROCKET AF Rivaroxaban versus warfarine dans la fibrillation atriale non valvulaire Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel.
FENOC Coût et résultats : comparaison de 2 agents bypass chez les patients atteints d’hémophilie A compliquée par un inhibiteur. Steen Carlsson K et al.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack CHANCE Wang Y et al. N Engl J Med 2013 ;369:11-19.
PRÉVENTION THROMBOSE KT & HÉMOPATHIES Prévention des thromboses sur cathéter veineux central par la nadroparine dans les hémopathies malignes : une étude.
Registre RIETE Maladie thrombo-embolique veineuse pendant la grossesse et le post-partum : résultats du registre RIETE. Blanco-Molina A et al. Thromb Haemost.
ISAR-SAFE, ITALIC, DAPT Durée de la bithérapie AAP post ATL-stent actif Schulz-Schüpke S, et al. ISAR-SAFE, Gilard M, et al. ITALIC, Mauri L, et al. DAPT.
Apixaban for Extended Treatment of Venous Thromboembolism Agnelli G, et al. N Engl J Med 2012 DOI : /NEJMoa AMPLIFY-EXT.
ESPRIT Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT) : randomised controlled trial The ESPRIT Study.
PROTECT Daltéparine versus héparine non fractionnée chez les patients de réanimation. Dalteparin versus unfractionated heparin in critically ill patients.
HEAT-PPCI Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI) : an open-label, single centre, randomised.
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS TIMI 51 ATLAS ACS 2 –TIMI 51 * Gibson CM.
D-dimère : déterminant de la durée du traitement anticoagulant pour TVP ? D-dimer testing to determine the duration of anticoagulation therapy. PROLONG.
Prophylaxie adulte Efficacité et sécurité de la prophylaxie secondaire vs le traitement à la demande chez l’adulte avec hémophilie A sévère : résultats.
TRA 2° P Vorapaxar in the secondary prevention in atherothrombotic events Morrow DA et al. N Engl J Med 2012 ; 366 : Morrow DA et al. ACC 2012.
ENGAGE-AF TIMI 48 Edoxaban versus warfarin in patients with atrial fibrillation. AHA 2013 Giugliano R.P, et al. N Engl J Med 2013 ; 369 :
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
ADVANCE-1 Apixaban ou enoxaparine pour la thromboprophylaxie après prothèse totale du genou Lassen MR et al. N Engl J Med 2009;361: Apixaban or.
RECORD4 Rivaroxaban versus enoxaparine pour la thromboprophylaxie après prothèse totale du genou (RECORD4) : essai randomisé Turpie AG et al. Lancet 2009;373:
PRoFESS Aspirine et dipyridamole à libération prolongée versus clopidogrel en prévention des récidives d’AVC : étude en double aveugle contrôlée par placebo.
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients Cohen AT, et al. N Engl J Med 2013 ; 368 : MAGELLAN.
Recombinant Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery ATLANTIC.
LCA Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism.
ACTIVE A Prévention des événements de la fibrillation auriculaire par le clopidogrel Effect of Clopidogrel added to Aspirin in patients with Atrial Fibrillation.
Prasugrel vs Clopidogrel for Acute Coronary Syndromes without Revascularization TRILOGY ACS Roe MT et al. N Engl J Med 2012 ; 367:
CHAMPION PHOENIX Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events Bhatt D.L, et al. N Engl J Med 2013 Bhatt DL et al. ACC 2013.
ATLAS ACS-TIMI 46 Rivaroxaban versus placebo dans le SCA
ACCOAST Pretreatment with prasugrel in non-ST elevation acute coronary syndromes ESC 2013 Montalescot G, et al. N Engl J Med 2013.
Dabigatran versus warfarin in patients with atrial fibrillation.
Platelet inhibition and patient outcomes
Host-ASSURE Adjunctive Cilostazol vs double dose clopidogrel after PCI with drug eluting stent Hyo-Soo K et al. ACC 2012.